ライフサイエンスコーパス: VLP vaccine

1 e P1 COBRA VLP and either the X3 or X6 COBRA VLP vaccine.

2 strated the immune potency of the formulated VLP vaccine.

3 to a surge of industry interest in exploring VLP vaccines.

4 have benefits for ZIKV and other flaviviral VLP vaccines.

5 cts as compared to those that received WS/05 VLP vaccines.

6 el that previously validated the efficacy of VLP vaccines.

7 cial requirement for validating manufactured VLP vaccines.

8 mically viable than the virus-like particle (VLP) vaccine.

9 intramuscular norovirus virus-like particle (VLP) vaccine.

10 he immunogenicity of a recombinant HPV-16 L1 VLP vaccine administered intramuscularly, without adjuva

11 aride preserved the HA activity of influenza VLP vaccines after microneedles were coated.

12 udy, we describe the development of a dengue VLP vaccine and demonstrate that it induces a robust imm

13 (PBMCs) from 43 individuals receiving the L1 VLP vaccine and from 10 individuals receiving placebo.

14 These results indicate that 2/6-VLP vaccines are immunogenic in gnotobiotic pigs when in

15 Whole-inactivated and virus-like particle (VLP) vaccines are 2 of the current approaches being eval

16 mavirus virion protein) virus-like particle (VLP) vaccines are regarded as safe, effective, and well

17 tential applications in the development of a VLP vaccine as well as small-molecule drugs targeting as

18 in the development of a virus-like particle (VLP) vaccine as well as small-molecule drugs targeting a

19 e, study day 22) with a single dose of CHIKV VLP vaccine, based on a four-fold increase of CHIKV neut

20 This study demonstrates that a VLP vaccine candidate containing a stabilized prefusion

21 Interestingly, the potential tetravalent VLP vaccine candidate provided strong neutralizing antib

22 .1 and GII.4c norovirus virus-like particle (VLP) vaccine candidate adjuvanted with alum and monophos

23 We have developed a virus-like particle (VLP) vaccine candidate for protection from RSV.

24 ed 2 bivalent norovirus virus-like particle (VLP) vaccine candidate formulations in healthy adults ag

25 da's bivalent norovirus virus-like particle (VLP) vaccine candidate in 50 healthy 18- to 49-year-olds

26 ization, with novel RSV virus-like particle (VLP) vaccine candidates containing stabilized prefusion

27 Using virus-like particle (VLP) vaccine candidates, we have directly compared VLPs

28 Virus-like particle (VLP) vaccines comprising CprME and subviral particle (SV

29 es are needed to evaluate whether and/or how VLP vaccines confer protection against genital HPV infec

30 recent studies have shown the ability of the VLP vaccines containing GP, NP, and VP40 to confer compl

31 replication and immunity, and shows that NV VLP vaccines could induce protective homologous immunity

32 These data demonstrate that an mpox VLP vaccine derived from three MPXV clade Ia proteins pr

33 controlled studies of a virus-like particle (VLP) vaccine derived from norovirus GI.1 genotype adjuva

34 .n.) doses of a rotavirus-like particle (2/6-VLPs) vaccine derived from Wa (VP6) and bovine RF (VP2)

35 double-layered rotavirus-like particle (2/6-VLPs) vaccines derived from simian SA11 or human (VP6) W

36 production is applicable to other flavivirus VLP vaccine development, due to the similarity in viral

37 the research and development that led to the VLP vaccines; discusses their safety, efficacy, and shor

38 re, we demonstrate that virus-like particle (VLP) vaccines elicit a protective neutralizing antibody

39 A B3 VLP vaccine elicited more robust neutralization of B3 su

40 accinated with a single dose of the COBRA HA VLP vaccines elicited antibodies with HAI activity again

41 ults demonstrate that a novel bivalent Ebola VLP vaccine elicits strong humoral and cellular immune r

42 against more H1N1 viruses in the panel than VLP vaccines expressing wild-type HA proteins.

43 than COBRA preimmune ferrets vaccinated with VLP vaccines expressing wild-type HA proteins.

44 accinating ferrets with virus-like particle (VLP) vaccines expressing COBRA HA proteins elicited anti

45 s, were vaccinated with virus-like particle (VLP) vaccines expressing either an HA from a wild-type H

46 easibility of an efficacious multivalent NoV VLP vaccine for future use in human populations.

47 ed work to date regarding development of the VLP vaccines for prevention of lethal filovirus hemorrha

48 e 6, 11, 16, and 18) L1 virus-like particle (VLP) vaccine (Gardasil).

49 e 6, 11, 16, and 18) L1 virus-like particle (VLP) vaccine (Gardasil).

50 uation of a Pfs47-based virus-like particle (VLP) vaccine generated by conjugating our 58 amino acid

51 volunteers immunized with a multivalent NoV VLP vaccine (genotypes GI.1/GII.4) were analyzed for IgG

52 Additionally, the two high-dose VLP vaccine groups generated NA-inhibiting antibodies th

53 cacy of the licensed L1 virus-like particle (VLP) vaccines has encouraged development of several seco

54 Filovirus VLP vaccines have used particles containing 2 or 3 (GP a

55 Virus-like particle (VLP) vaccines have realized promising results when teste

56 reactive immune responses elicited by a 1918 VLP vaccine in a murine model.

57 to the homologous protective efficacy of the VLP vaccine in humans (47%).

58 sults of this study support the use of CHIKV VLP vaccine in individuals with previous alphavirus vacc

59 rticle vaccine was comparable to that of the VLP vaccine in pigs (60%) and to the homologous protecti

60 articles to permit the direct testing of HPV VLP vaccines in rabbits.

61 ccessfully demonstrated efficacy of bivalent VLP vaccines in rodents; more recent studies have shown

62 s in the development of second-generation L1 VLP vaccines in terms of cost reduction-eg, by productio

63 chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of heterologous alph

64 ibe the construction of virus-like particle (VLP) vaccines in which modified M1, A35 and B6 proteins

65 on with influenza A/PR8 virus-like particle (VLP) vaccine, in vivo and in vitro vaccine antigen-speci

66 This chimeric L1/L2 VLP vaccine induced persistent immune responses and prot

67 This candidate HPV VLP vaccine induced robust B and T cell responses, and T

68 Multivalent VLP vaccines induced robust receptor-blocking antibody r

69 Importantly, our results show that VLP vaccine-induced CD8 T cell-mediated protection is no

70 Vaccination with a multivalent NoV VLP vaccine induces a broadly blocking Ab response to mu

71 These results indicate that the Abeta-VLP vaccine induces an effective humoral immune response

72 Overall, the Flu-RBD VLP vaccine is a promising candidate for combating COVID

73 These results indicate that our dengue VLP vaccine is a promising vaccine candidate.

74 In addition, the COBRA VLP vaccine is more effective than a homologous vaccine

75 ed with H5N1 A/Indonesia/05/2005 (clade 2.1) VLP vaccine manufactured in Sf9 insect cells.

76 ade-specific responses and suggests an HPV16 VLP vaccine may have broader protection that initially a

77 transplant recipients with a multivalent BKV VLP vaccine might reduce the risk of developing posttran

78 te the nanoparticle and virus-like particle (VLP) vaccine molecules from host cell proteins and other

79 ed vaccines or help to re-formulate existing VLP vaccines not naturally carrying immunostimulatory se

80 ularly administered one 40 mug dose of CHIKV VLP vaccine on day 1.

81 randomized to 2 doses of intranasal Norwalk VLP vaccine or controls 21 days apart.

82 ation, whereas chimpanzees that received GII VLPs vaccine or a placebo were not.

83 vercome this, we used a virus-like particle (VLP) vaccine platform (PP7) for conformationally-restric

84 In summary, this B19 VLP-vaccine platform produced high (> or =2.0 x 10(5)) a

85 It is generally assumed that VLP vaccines protect by inducing type-specific neutraliz

86 Current L1 virus-like particle (VLP) vaccines provide type-restricted protection against

87 nst virus shedding, while the P particle and VLP vaccines provided cross-variant protection (47% and

88 This norovirus VLP vaccine provides protection against illness and infe

89 Bivalent norovirus VLP vaccine reduced norovirus-related vomiting and/or di

90 Additionally, the VLP vaccine reduces the replication and spread of the vi

91 Immunization with alphavirus VLP vaccines represents a strategy to contain the spread

92 - and betaHPVs, we developed a two-component VLP vaccine, RG2-VLP, in which L2 protective epitopes de

93 Mice administered a multivalent VLP vaccine showed high-titer serum antibody responses t

94 anasal immunization with a monovalent GI NoV VLP vaccine showed proof-of-concept efficacy.

95 d provides an update on virus-like particle (VLP) vaccine studies.

96 Licensed L1 virus-like particle (VLP) vaccines, such as Gardasil 9, target a subset of al

97 rces for screening or highly multivalent HPV VLP vaccines, suggesting the need for a low-cost, broadl

98 HAI activity after vaccination with COBRA HA VLP vaccines than COBRA preimmune ferrets vaccinated wit

99 development and immunogenicity of SARS-CoV-2 VLP vaccine that incorporates the four structural protei

100 valent, spherical Ebola virus-like particle (VLP) vaccine that incorporates glycoproteins (GPs) from

101 n and use of virus-free virus-like particle (VLP) vaccines that mimic the "empty" capsids (ECs) norma

102 vaccine, is the first second-generation HPV VLP vaccine to be available on the market.

103 Results of VLP vaccine trials appear promising.

104 Vaccination with a monovalent HPV-16 L1 VLP vaccine was associated with modulation of genes invo

105 The chikungunya VLP vaccine was immunogenic, safe, and well tolerated.

106 immunogenicity of a yeast-derived HPV-11 L1 VLP vaccine was tested in women.

107 The intranasal monovalent adjuvanted Norwalk VLP vaccine was well tolerated and highly immunogenic an

108 CHIKV VLP vaccine was well tolerated and similarly immunogenic

109 Both candidate VLP vaccines were well tolerated and elicited robust imm

110 an papillomavirus (HPV) virus-like particle (VLP) vaccines were recently licensed.

111 nti-hRSV approaches are virus-like particle (VLP) vaccines, which, based on resemblance to virus or v

112 I) antibody titers than antisera elicited by VLP vaccines with wild-type HA VLPs in preimmune ferrets

113 s GI.1/GII.4 bivalent vaccine-like particle (VLP) vaccine with 3-O-desacyl-4'-monophosphoryl lipid A

114 to develop a SARS-CoV-2 virus-like particle (VLP) vaccine with two-hit protection.

115 istered multivalent norovirus-like particle (VLP) vaccines with alphavirus adjuvant particles to mice

116 ally delivered norovirus viruslike particle (VLP) vaccine (with chitosan and monophosphoryl lipid A a